Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
IntroductionHepatocellular carcinoma (HCC) represents the fifth most common cancer and the third most leading cause of cancer-related deaths worldwide. 1 High morbidity observed in HCC is majorly attributed to the lack of early detection markers and poor prognosis. Hence, exploration of novel frontiers in HCC diagnosis and therapeutics remains to be high priority research areas. 2,3 HCC represents a public health problem in Egypt. It constitutes 70.48% of all liver tumors among Egyptians, representing the second most common malignancy after bladder cancer in men and breast cancer in women and the second most common cause of death in men. 4,5 Alpha-fetoprotein (AFP) is the most widely used tumor biomarker for HCC diagnosis. However, it has low sensitivity and specificity. This highlights the need for other methods that would be minimally invasive, simple, and reliable. 6 MicroRNAs (miRNAs) are a class of short non-coding RNAs, which play a central role in sequence specific posttranscriptional gene attenuation. 7 They are involved in various fundamental cellular processes as well as carcinogenesis. Moreover, miRNAs are highly stable in serum due to their resistance to RNase, extreme pH, and temperature. Therefore, they have been identified as candidate
AbstractThere is an obvious need to diagnose hepatocellular carcinoma using novel non-invasive and sensitive biomarkers. In this regard, the aim of this study was to evaluate and correlate both relative quantification of microRNA-7 using quantitative real time polymerase chain reaction and quantitative analysis of selenoprotein P using enzyme-linked immunosorbent assay in sera of hepatocellular carcinoma patients, chronic liver disease patients, as well as normal healthy subjects in order to establish a new diagnostic biomarker with a valid non-invasive technique. In addition, this study aimed to investigate whether changes in selenium supply affect microRNA-7 expression and selenoprotein P levels in human hepatocarcinoma cell line (HepG2). The results showed a highly significant decrease in serum microRNA-7 relative quantification values and selenoprotein P levels in malignant group in comparison with benign and control groups. The best cutoff for serum microRNA-7 and selenoprotein P to discriminate hepatocellular carcinoma group from benign and control groups was 0.06 and 4.30 mg/L, respectively. Furthermore, this study showed that changes in selenium supply to HepG2 cell line can alter the microRNA-7 profile and are paralleled by changes in the concentration of its target protein (selenoprotein P). Hence, serum microRNA-7 ...